MRC Confidence in Concept (CiC6) Fund 2019 Call guidance

The MRC Confidence in Concept (CiC) scheme provides funding to institutions to support the earliest stages of translational research projects

Through the complementary skills at each institution, we will create the critical mass necessary for UK researchers, interested in translating their research into health benefits, to compete in an increasingly competitive international market. The aim of the partnership is to deliver a high number of scientifically excellent translational proposals.

We would see the outcome of the funding is the prioritisation of translational research based on potential medical impact and ‘developability’ and significant acceleration in time to product delivery.

The MRC Confidence in Concept (CiC) scheme provides funding to institutions to support the earliest stages of translational research projects. The Tropical Infectious Disease Consortium has been successful in gaining an award under this scheme which will be allocated to eligible projects via an open, competitive and externally peer-reviewed process.

The fund will provide awards, typically in the region of £50k (higher award values will be considered for those projects that incur higher running costs), for projects (lasting between 6 and 18 months) that accelerate the transition from discovery science into the early/late stages of therapeutic, diagnostic and vaccine development by supporting key feasibility studies to establish the viability of an approach or generate the materials/technologies for ongoing translational activity. The fund is intended to accelerate relevant translational activities so projects should aim to provide sufficient preliminary data to establish the viability of an approach and the market need for its outputs – i.e. to provide confidence in the underlying concept that would leverage more substantive funding from external funders.

The earliest start date for projects is 1 October 2019. The project end date cannot go beyond 31 March 2021.

Projects within the following categories will be eligible to apply:

• Diagnostics
• Therapeutics
• Vaccines
• Vector control tools
• Translational focussed Informatics
• Translational enabling technologies

Projects should be at the stage whereby CiC funding would develop the approach to a point where it would be capable of successfully applying for larger external translational funding sources e.g. MRC DPFS.

The funding is not intended to support:

• Early stage “blue skies” research
• Entire translational projects;
• Staff between posts (i.e. bridging support) or PhD studentships;
• Continuation of research grants;
• Projects that have already failed in competitive grant applications (without clear justification)
• Costs relating to commercialisation or the protection of intellectual property.

Applications are required to have a Principal Investigator from one of the Consortium’s partner institutions and projects from more than one partner institution are encouraged. Applications with SMEs/Pharma will attract a higher weighting within the scoring process, but these must be led by the academic PI. Please note that attachments to the application form will not be considered and if any are included with the submission they will be removed before being sent to ESAC members.

Scoring, selection and assessment criteria

Eligible applications will be reviewed by an External Scientific Advisory Committee (ESAC) which is composed of specialists with industrial experience in product discovery and development. The ESAC will review, assess and score the applications to independently advise the Senior Management Group of the Consortium on the appropriateness and “fit” of the projects for funding under the CiC programme.

Criteria for assessment of the applications are:
• Research quality
• Development pathway
• Track record of a research team
• Value for money
• Potential impact
• SME/Pharma involvement

Due to the anticipated high volume of applications to be received, it will not be possible to give individual feedback on unsuccessful applications.

Reporting: it is a mandatory requirement if your project is funded that all awardees will be required to provide interim and final reports via Researchfish.

Transparency and conflict of interest

LSTM and the Consortium are committed to transparency throughout the decision-making process and it is important to us to manage all real, potential or apparent conflicts of interest with integrity, impartiality, honesty, and openness. Any ESAC member who has a conflict of interest on any submitted project will be asked to declare it, and they will not score that particular project, with the scoring average being adjusted accordingly. A weighting will be added to the score if the project includes SME/Pharma partners.

The final decision on which projects to fund within the funding envelope will be made, based on the weighted average of the ESAC scores, by the Senior Management Group of the Consortium at a meeting in June 2018. Members of the Senior Management Group will be asked to declare any conflict of interest at the start of the meeting and will be requested to leave the meeting when individual project discussions are taking place.

Detailed minutes of the meeting will be taken and available for inspection. Further details of how to identify a potential conflict of interest, the scoring methodology and how the final list of projects will be selected can be found here and here If you would like to see the minutes at the end of the process please contact the Research Management Services team on

The application form can be found here.

Application documents

Please note that attachments to the application form will not be considered and if any are included with the submission they will be removed before being sent to ESAC members.  Please limit Publications References to 10 max and add them the end of the document

The Closing date is 4PM on Monday 5 August 2019.

It is anticipated that decisions on awards will be issued in September 2019.